Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 10mg.
Immune cells decide how to respond, not only whether to. Thymosin alpha-1 is studied for its part in that decision.
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from the thymus, the organ where T cells mature; its synthetic form is thymalfasin. It is studied because it changes how dendritic cells and T cells respond to signals, a question of immune coordination rather than tissue repair. Mechanism evidence comes from mouse and cell work; human trials of thymalfasin have been in patients with chronic hepatitis B and certain cancers. Supplied for laboratory research.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 10mg | TA1 | In stock | $120 |
No batch-specific test report is currently published for this product. What a report does and does not show.
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
Thymosin alpha-1 is not an approved medicine in Australia. The synthetic form, thymalfasin (marketed as Zadaxin), is not approved by the US FDA; registrations reported in other countries for chronic hepatitis B were not individually verified against a regulator record for this note.
Status checked 2026-09-23. Details and sources in the research note.